检索范围:
排序: 展示方式:
Case report of neurofibromatosis type 1 combined with primary ciliary dyskinesia
《医学前沿(英文)》 2021年 第15卷 第6期 页码 933-937 doi: 10.1007/s11684-021-0860-7
关键词: primary ciliary dyskinesia neurofibromatosis bronchiectasis transmission electron microscopy genetic sequencing
Clinical characteristics of pulmonary hypertension in bronchiectasis
null
《医学前沿(英文)》 2016年 第10卷 第3期 页码 336-344 doi: 10.1007/s11684-016-0461-z
Pulmonary hypertension (PH), as a complication of bronchiectasis, is associated with increased mortality. However, hemodynamic characteristics and the efficacy of pulmonary arterial hypertension (PAH) therapies in patients with bronchiectasis and PH remain unknown. Patients with bilateral bronchiectasis and concurrent PH were included in the study. Patient characteristics at baseline and during follow-up, as well as survival, were analyzed. This observational study was conducted in 36 patients with a mean age of 51.5 years (range, 17?74 years). The 6 min walking distance was 300.8±93.3 m. The mean pulmonary arterial pressure (PAP) was 41.5±11.7 mmHg, cardiac output was 5.2±1.4 L/min, and pulmonary vascular resistance was 561.5±281.5 dyn·s·cm−5. The mean PAP was>35 mmHg in 75% of the cases. Mean PAP was inversely correlated with arterial oxygen saturation values (r = −0.45, P = 0.02). In 24 patients who received oral PAH therapy, systolic PAP was reduced from 82.4±27.0 mmHg to 65.5±20.9 mmHg (P = 0.025) on echocardiography after a median of 6 months of follow-up. The overall probability of survival was 97.1% at 1 year, 83.4% at 3 years, and 64.5% at 5 years. Given the results, we conclude that PH with severe hemodynamic impairment can occur in patients with bilateral bronchiectasis, and PAH therapy might improve hemodynamics in such patients. Prospective clinical trials focusing on this patient population are warranted.
标题 作者 时间 类型 操作